source
- Beeline Medicines raises $126.3M, bringing total Series A funding to $426.3M for immune‑drug developmentBeeline Medicines announced an additional $126.3 million in Series A financing, pushing the total raised to $426.3 million. The capital boost was disclosed on Tuesday and follows an earlier spring…
- Beeline Medicines secures $126M from Bain Capital, CPPIB and Bristol Myers to expand immunology pipelineBeeline Medicines, a spinout from Bristol Myers Squibb, announced it has received an additional $126 million in financing. The new capital comes from existing investors Bain Capital and the Canada…